Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935995 | 0.85 | SCN9A (0.41) | TGFBR1NTRK1IRAK4JAK2CSNK2A2 | |
| SCHEMBL16936085 | 0.84 | NTRK1 (0.45) | TGFBR1NTRK1IRAK4JAK2NTRK3 | |
| SCHEMBL21045868 | 0.80 | IRAK4 (0.41) | TGFBR1NTRK1IRAK4 | |
| SCHEMBL16936000 | 0.78 | TGFBR1 (0.40) | TGFBR1NTRK1JAK2CSNK2A1 | |
| SCHEMBL16946714 | 0.76 | IRAK4 (0.42) | TGFBR1NTRK1IRAK4JAK2JAK1 | |
| SCHEMBL21229250 | 0.76 | NTRK1 (0.43) | NTRK1IRAK4JAK2SMPD3NTRK3 | |
| SCHEMBL21838100 | 0.69 | NTRK1 (0.47) | TGFBR1NTRK1JAK2 | |
| SCHEMBL16936088 | 0.69 | NTRK1 (0.44) | NTRK1JAK2CSNK2A2CSNK2A1 | |
| SCHEMBL16946723 | 0.69 | NTRK1 (0.50) | TGFBR1NTRK1JAK2TYK2SMPD3 | |
| SCHEMBL16947003 | 0.69 | NTRK1 (0.32) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3636650-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| EP-3097107-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-3097107-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP Therapeutics, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015112806-A2 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | TGFBR1 3933/4885NTRK1 935/4885IRAK4 340/4885 |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | TGFBR1 4041/4885NTRK1 1072/4885IRAK4 343/4885 |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | TGFBR1 4041/4885NTRK1 1072/4885IRAK4 343/4885 |
| US-20200216465-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | TGFBR1 4041/4885NTRK1 1072/4885IRAK4 343/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | TGFBR1 4041/4885NTRK1 1072/4885IRAK4 343/4885 |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | TGFBR1 4041/4885NTRK1 1072/4885IRAK4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.